Trials / Unknown
UnknownNCT05142631
Fruquintinib in the Treatment of Soft Tissue Sarcoma
Single Center, Open, Single Arm Phase II Clinical Study of Fruquintinib in the Treatment of Soft Tissue Sarcoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of Fruquintinib in patients with chemotherapy insensitive or chemotherapy resistant soft tissue sarcoma
Detailed description
This trial is an open, single arm, single center, prospective phase II clinical study. Objective:To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib | To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma. |
Timeline
- Start date
- 2021-11-21
- Primary completion
- 2023-05-30
- Completion
- 2023-08-30
- First posted
- 2021-12-02
- Last updated
- 2022-03-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05142631. Inclusion in this directory is not an endorsement.